Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLCP-063-1
- Development stage
- Preclinical
- Lead developer
- Galenicap
- Modality
- Small Molecules
01
Overview
GLCP-063-1 is a small molecule therapeutic candidate developed by Galenicap for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common and often dose-limiting side effect of cancer treatments such as taxanes, platinum-based agents, and vinca alkaloids, manifesting as sensory loss, tingling, and neuropathic pain. GLCP-063-1 is described as a first-in-class agent, although its specific biological target and mechanism of action remain proprietary and have not been publicly disclosed by the sponsor. The program is currently in the discovery or preclinical stage of development.
- Other names
- GLCP-063-1GLCP063-1GLCP 063-1
Beyond the preview
Go deeper on GLCP-063-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLCP-063-1.